Danaher Corporation logo

Danaher CorporationNYSE: DHR

Health Care · Life Sciences Tools & Services

$175.47

-1.95%

Vol: 5.1M

Research Digest

Friday, May 1, 2026

Positive

Danaher secures EUR 2.98B in financing for Masimo acquisition and reports Q1 earnings beat with strong bioprocessing recovery

Danaher issued EUR 3 billion in senior notes on April 29 with net proceeds of EUR 2.98 billion to finance the Masimo $9.9B acquisition. Q1 2026 adjusted EPS of $2.06 beat expectations despite revenue miss at $5.95B (up 3.5% YoY). Management guides 3%-6% 2026 growth driven by bioprocessing, life sciences recovery, and diagnostics stabilization. Board approved $0.40/share quarterly dividend. Analyst consensus is Strong Buy with 12-month target of $241.69.

Price 50d 200d

Previous Market Intelligence

13 days
Apr 30Danaher issues €3B in Euro notes to fund Masimo acquisitionPositive

Danaher issued €3 billion in senior notes on April 29 to finance the Masimo acquisition, with net proceeds of approximately €2.98 billion. The acquisition addresses Danaher's strategy to strengthen its diagnostics portfolio with pulse oximeter technology. Mandatory redemption occurs if the deal does not close by mid-November 2026. Company reported Q1 EPS of $2.06, beating estimates of $1.94. Management expects 3-6% growth in 2026 driven by bioprocessing and diagnostics stabilization. The acquisition financing indicates management confidence in closing the deal and expanding the healthcare technology portfolio.

Apr 29Danaher raises 2026 EPS guidance to $8.35-$8.55 after 9.5% Q1 adjusted EPS growth to $2.06Positive

Danaher reported Q1 2026 adjusted EPS of $2.06, up 9.5% YoY, beating analyst estimates of $1.94. Revenues increased 3.5% to $6.0B with non-GAAP core revenue +0.5% YoY. Management raised the top end of 2026 adjusted EPS guidance by $0.05 to $8.35-$8.55, signaling confidence in growth. The company's $9.9B acquisition of pulse oximeter maker Masimo strengthens its diagnostics portfolio. 2026 outlook expects 3%-6% growth driven by bioprocessing, life sciences recovery, and diagnostics stabilization.

Apr 16Goldman Sachs cuts Danaher price target to $230 from $265; Q1 2026 earnings call scheduled for April 21Mixed

Danaher faces analyst headwinds with Goldman Sachs cutting its price target to $230 from $265 on April 16, while Jefferies and Wolfe Research also trimmed targets. The company announced a quarterly dividend of $0.40 per share, payable April 24. Q1 2026 earnings will be reported on April 21 at 8:00 a.m. ET. Pre-market trading at $196, up 2.61% overnight. Recent reports indicate Danaher is planning to acquire Masimo (pulse oximeter maker) for $9.9 billion to expand diagnostics portfolio.

Apr 14Danaher pursues $9.9B Masimo acquisition; Q4 EPS beat; Q1 earnings April 21Positive

Acquiring Masimo for ~$9.9B including debt. Q4 EPS $2.23 beat estimates. Q1 earnings April 21 with $1.94 EPS expected. Consensus Strong Buy $248.60 PT.

Apr 13Danaher advances toward Masimo acquisition; Q1 2026 earnings call set for April 21Positive

Danaher scheduled Q1 2026 earnings call for April 21, 2026. Announced regular quarterly dividend of $0.40/share (payable April 24). Masimo acquisition progressing; expected to strengthen diagnostics franchise. Analysts maintain Strong Buy with $264.05 price target (20.2% upside). Q4 2025 EPS beat: $2.23 vs $2.17 estimate.

Apr 10Danaher scheduled to release Q1 2026 earnings April 21 with Masimo acquisition advancing diagnostics portfolio.Positive

Danaher will announce Q1 2026 results on April 21. Analysts expecting $1.94 EPS (+3.2% YoY). Declared quarterly dividend of $0.40/share payable April 24. Announced $9.9B acquisition of Masimo Corporation. Q4 2025 EPS was $2.23 beating $2.17 estimate. Evercore ISI maintains Outperform but lowered target from $254 to $225.

Apr 9Danaher Q4 earnings miss expectations, board approves dividendNeutral

Danaher dropped after Q4 2025 results with mixed fundamentals. Board approved $0.40/share quarterly dividend payable April 24. Stock recovered 2.71% to $196.19 with analysts maintaining Strong Buy at $264.05 target (20.2% upside), though price targets cut amid cautious guidance.

Apr 8Danaher schedules Q1 2026 earnings for April 21; Masimo acquisition set for H2 2026.Neutral

Danaher scheduled Q1 2026 earnings call April 21 at 8am ET. Board approved quarterly dividend $0.40 payable April 24. $9.9 billion Masimo acquisition expected to close H2 2026. Beckman Coulter entered AI collaboration with Innovaccer.

Apr 7Danaher schedules Q1 2026 earnings call for April 21 amid $9.9B Masimo acquisition progress.Neutral

Danaher announced a definitive agreement to acquire Masimo Corporation for approximately $9.9 billion in cash, with close expected in H2 2026. CEO Rainer Blair projected 2026 revenue growth of 3%-6% with 100-basis-point operating margin expansion. Q4 2025 net earnings reached $1.2 billion ($1.66 per share) with full-year earnings of $3.6 billion ($5.03 per share). The company declared a regular quarterly dividend of $0.40 per share payable April 24. Q1 2026 earnings call is scheduled for April 21, 2026 at 8:00 a.m. ET.

Apr 6Danaher to acquire Masimo for $9.9B; Q1 earnings April 21.Positive

DHR agreed to acquire Masimo at $180/share ($9.9B EV), expected close H2 2026. Masimo projected $530M+ EBITDA in 2027 with $125M+ cost synergies. FY2026 guidance: core revenue +3-6%, adjusted EPS $8.35-8.50. Q1 earnings April 21.

Apr 3Danaher acquires Masimo in ~$10B deal; Q4 2025 sales beat; quarterly dividend approved at $0.40/share.Positive

Danaher entered definitive agreement to acquire Masimo in nearly $10 billion deal. Q4 2025 sales of $6.84 billion beat consensus at $6.81 billion (up 4.5% YoY). Operating cash flow of $2.1 billion and free cash flow of $1.8 billion. Subsidiaries launched innovations. Board approved $0.40/share quarterly dividend payable April 24. 16 analysts rate Strong Buy with 12-month target of $250.56.

Apr 1Danaher Corp schedules Q1 2026 earnings call for April 21 as stock down 20% year-to-date.Neutral

Danaher will host its first quarter 2026 earnings conference call on April 21, 2026. The company declared a $0.40 quarterly dividend payable April 24, 2026. Stock performance has been weak with 19.7% decline in 2026, reflecting concerns about the $9.9 billion Masimo acquisition and uncertainty around bioprocessing growth. Management has guided for low-single-digit core revenue growth in Q1. Analysts maintain consensus $239 price target.

Mar 31Danaher announced $9.9B Masimo acquisition for $180/share; Q4 earnings beat.Positive

Danaher Q4 sales $6.84B up 4.5% YoY beating consensus. EPS $2.23 exceeded $2.17 guidance. Acquiring Masimo for $9.9B closing H2 2026. Quarterly dividend $0.40. Stock down 20% YTD. 16 analysts Strong Buy with $250.56 target.

Sector Peers

CompanyPriceDay1MFwd P/EBetaMkt Cap
TMOTHERMO$469.56-1.96%-1.9%17.5x0.97$178.0B
DHRDANAHER$175.47-1.95%-6.9%19.7x0.99$126.7B
AAGILENT$114.69-0.74%+0.6%17.6x1.30$32.7B
WATWATERS$306.56-0.86%+1.7%18.9x1.20$30.4B
IQVIQVIA$157.04-0.84%-7.2%11.3x1.39$26.6B
MTDMETTLER$1,269.64-0.55%+0.8%24.9x1.44$25.8B

Key Fundamentals

Market Cap$126.7B
P/E (TTM)34.6
Forward P/E19.7
Beta0.99
Div Yield89.00%
Prev Close$178.95

RSI (14-Day)

33Neutral
0305070100

52-Week Range

$175.00$175.47$242.80
From High-27.7%
From Low+0.3%

Moving Averages

50d SMA
$194.30-9.7%
200d SMA
$208.60-15.9%

Price below 200d MA — bearish structure.

Historical Returns

1W
-4.7%
1M
-4.6%
3M
-21.9%
6M
-20.5%
1Y
-10.0%
YTD
-23.8%

Volume

Today5.1M
20d Avg4.4M
Ratio1.16x